Oxurion NV Logo

Oxurion NV

Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.

OXUR | BR

Overview

Corporate Details

ISIN(s):
BE0974487192
LEI:
549300VWY8KVDFKLDM59
Country:
Belgium
Address:
Gaston Geenslaan 1, 3001 Heverlee
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Oxurion is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Its ambition is to build an integrated group of subcontractors to serve healthcare stakeholders. The company holds a 72% stake in Axiodis CRO, a contract research organization specialized in biometrics. This strategy represents a shift from its historical focus as a biopharmaceutical company developing therapies for retinal diseases like Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20251002.pdf
English 352.2 KB
2025-10-02 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20251002.pdf
Dutch 378.2 KB
2025-09-30 18:00
Interim Report
OXUR GLOBAL - Financial report 30-06-2025 (EN) FINAL.pdf
English 412.9 KB
2025-09-30 18:00
Interim Report
OXUR GLOBAL - Financial report 30-06-2025 (NL) FINAL.pdf
Dutch 420.8 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publish-H1-2025-results_EN.pdf
English 211.4 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publication-H1-2025-resultats_FR.pdf
French 161.8 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publicatie-H1-2025-resultaten_NL.pdf
Dutch 211.0 KB
2025-09-08 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250903.pdf
English 371.9 KB
2025-09-08 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250903.pdf
Dutch 396.3 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-EN-20250901.pdf
English 190.2 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-FR-20250901.pdf
French 125.2 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-NL-20250901-1.pdf
Dutch 214.2 KB
2025-09-01 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250901.pdf
English 1.2 MB
2025-09-01 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250901.pdf
English 1.3 MB
2025-08-07 18:00
Legal Proceedings Report
OXUR-New-Development-Strategy-EN-20250806.pdf
English 195.7 KB

Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxurion NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-07 Bareldam SA Close relation Buy 1,180,555 1,700,000.00 EUR
2021-09-30 Lavinia D. Clay 2009 Revocable Trust Close relation Other 2,766,337 5,601,002.52 EUR

Peer Companies

Company Country Ticker View
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.